1. Apoptosis Epigenetics Cell Cycle/DNA Damage
  2. Apoptosis HDAC
  3. JNJ-16241199

JNJ-16241199  (Synonyms: R306465)

目录号: HY-10226
产品使用指南

JNJ-16241199 是一种具有口服活性的选择性 hydroxamate-based histone deacetylase (HDAC) 抑制剂,对 HDAC 1HDAC8IC50 分别为 3.3 nM 和 23 nM。JNJ-16241199 诱导组蛋白 3 乙酰化,并显著上调 A2780 卵巢癌细胞中 p21waf1, cip1 的表达。JNJ-16241199 诱导细胞凋亡 (cell apoptosis),并在多种人类恶性肿瘤中显示抗癌活性。JNJ-16241199 可用于癌症研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

JNJ-16241199 Chemical Structure

JNJ-16241199 Chemical Structure

CAS No. : 604769-01-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

JNJ-16241199 is an orally active, selective hydroxamate-based histone deacetylase (HDAC) inhibitor, with the IC50 of 3.3 nM and 23 nM for HDAC1 and HDAC8, respectively. JNJ-16241199 induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells. JNJ-16241199 induces cell apoptosis and shows anticancer activity in a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1].

IC50 & Target

HDAC1

3.3 nM (IC50)

HDAC8

23 nM (IC50)

体外研究
(In Vitro)

JNJ-16241199 对性淋巴细胞白血病 (ALL)、急性髓性白血病 (AML)、慢性淋巴细胞白血病 (CLL)、慢性髓性白血病 (CML)、淋巴瘤和骨髓瘤细胞具有抑制增殖作用 (IC50 = 15-486 nM) [1]
JNJ-16241199 抑制原代人乳腺上皮细胞 (HMEC) 增殖,IC50 值为 32 nM,对静止的非增殖 HMEC 细胞不敏感 (IC50 值为 7815 nM) [1]
JNJ-16241199 (0.1, 0.3, 1 μM, 24-48 h) 可以诱导 A2780 细胞发生细胞凋亡,并抑制其血管生成[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: Human A2780 ovarian carcinoma cells
Concentration: 0, 0.1, 0.3, 1 μM
Incubation Time: 24 h or 48 h
Result: Decreased in S phase at 300 nM, with a parallel increase in G1 phase, but increased in the sub-G1 fraction of cells at the 1 μM after 24 h.
Increased in sub-G1 phase at all active concentrations starting from 100 nM after 48 h.
体内研究
(In Vivo)

JNJ-16241199 (每天 10-40 mpk,连续 28 天,p.o) 抑制 A2780 卵巢癌、H460 肺癌和 HCT116 结肠癌原位异种移植肿瘤模型小鼠中肿瘤的生长[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Human A2780, H460 and HCT116 orthotopic xenograft tumor models[1]
Dosage: 10-40 mpk/day for 28 days
Administration: Oral gavage (p.o.)
Result: Induced H3 acetylation and p21waf1, cip1 promoter activity in A2780 ovarian tumour tissue.
Decreased tumour volume in three orthotopic xenograft tumor models.
Reached maximal decrease in final tumour volume to 76–87% in human A2780 orthotopic xenograft tumor models.
分子量

413.45

Formula

C19H19N5O4S

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
JNJ-16241199
目录号:
HY-10226
需求量: